(1S,2S)-2-[(1S)-1-carboxy-1-(9H-xanthen-9-ylamino)ethyl]cyclopropane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (1S,2S)-2-[(1S)-1-carboxy-1-(9H-xanthen-9-ylamino)ethyl]cyclopropane-1-carboxylic acid
• 化学式: C₂₀H₁₉NO₅
• 分子量: 353.4
• InChiKey: MQTUELGKDMBKBI-YRVVQQKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
  申请人：Di Paolo Therese

  公开号：US20140228398A1

  公开（公告）日：2014-08-14

  The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.
• MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190345148A1

  公开（公告）日：2019-11-14

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.